SOLUTRANS
26.10.2021 08:02:12 CEST | Business Wire | Press release
SOLUTRANS , the global hub for heavy and light commercial vehicles, will hold its 16th edition from 16 to 20 November 2021 in Lyon Eurexpo (France). Nearly 60,000 professionals, 1,000 exhibitors and brands are expected to attend this international event focusing on economic recovery and innovation, certified by the OICA (International Organization of Motor Vehicle Manufacturers).
This edition will showcase two major additions. Firstly, a "SOLUTRANS 4.0" hall dedicated to innovation for transport professionals. Secondly, the chance for professionals from all over the world to take part in the show remotely via the SOLUTRANS DIGITAL SHOW.
HGV manufacturers will be in attendance
The leading HGV manufacturers, such as DAF, IVECO, MAN, Mercedes, Renault Trucks, SCANIA and VOLVO will be exhibiting at SOLUTRANS. The largest bodywork manufacturers, vehicle fitters and service companies will also be present, as well as new names in the sector such as FORD TRUCKS, IRIZAR and VOLTA TRUCKS, who will be taking part for the first time in France.
SOLUTRANS 4.0, the hall of new technologies
This hall will present disruptive innovations and new names in the sector in all areas, from engineering to industry as well as IT solutions.
The objective of SOLUTRANS 4.0 is to foster the implementation of new solutions to optimize activity and overcome the challenges in the sector: energy transition, artificial intelligence, cybersecurity, recycling, etc.
Innovation gets the green light at SOLUTRANS !
All the innovations will be presented during the various award ceremonies that will take place during the trade show. The I-nnovation Awards have been further enriched this year and include a new prize: the "Digital AWARD". Also, for the fourth consecutive edition, SOLUTRANS will host the International Awards: ITOY, IVOTY, IPUA and TRUCK INNOVATION AWARD. These awards, recognized by the industry as a whole, reward the excellence of manufacturers and showcase the trends in the industrial and urban vehicle sector.
The theme of innovation will also be highlighted during the event via a broad range of conferences covering a variety of topics that respond to the challenges of the sector.
Finally, SOLUTRANS, in partnership with TotalEnergies, will be offering a new, completely redesigned and larger testing area to meet the needs of visitors and manufacturers of heavy and light commercial vehicles. The track has also been extended and re-designed with a 25 km semi-urban route to allow professionals to test the vehicles around the park.
SOLUTRANS DIGITAL SHOW: unlimited online access to the trade show
The SOLUTRANS DIGITAL SHOW, the virtual edition of the physical exhibition, will offer registered visitors, wherever they are located in the world, an interactive space where they can visit exhibitors' stands, contact their representatives and discover their new products… it’s all just click away! Two weeks before the actual trade show, registered visitors will be able to start making appointments with exhibitors and take advantage of the three additional days of opening to consult an exhibitor's offer online, thus giving them a chance to contact businesses that they wouldn’t have had time to meet during the physical edition of the trade show. They will also have access to conferences and other events, which will be broadcast live.
Discover the whole program of the SOLUTRANS 2021 trade show on solutrans.eu
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom